I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelop

TO TOO STORED Case 8821L\$

TE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of

SASWATI (NMN) DATTA, ET AL.

Serial No.: 10/027,646

Group Art Unit: 1725

Examiner: Filed: December 21, 2001

Confirmation No.: 1492

Portable Apparatus and Method For Treating a Workpiece For:

INFORMATION DISCLOSURE STATEMENT

Commissioner For Patents Washington, D.C. 20231

Dear Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, record is being made below in a Form PTO/SB08 of documents which the Patent Office may wish to consider in connection with examination of the aboveidentified patent application. It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case. As provided in §1.97(g), no representation is made or intended that a thorough art search was made. As provided in 37 C.F.R. §1.97(h), this Information Disclosure Statement does not constitute an admission of any kind, and specifically is not an admission that the documents listed on attached form PTO/SB08 are, or are considered to be, material to the patentability of the above-identified patent application, as defined in 37 C.F.R. §1.56(b).

X 37 C.F.R. §1.97 (b)(1) - U.S. Direct (within 3-months of filing a regular application or converted provisional)

This information disclosure statement, submitted under 37 C.F.R. §1.97 (b)(1), is being filed within three months of the filing date of a national application. Therefore, no fee is believed to be due.

37 C.F.R. §1.97 (b)(2) - Via PCT (within 3 mo. of Nat'l Stage Entry) 2.

This information disclosure statement, submitted under 37 C.F.R. §1.97 (b)(2), is being filed within three months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 in an international application. Therefore, no fee is believed to be due.

 $\frac{.}{3}$. $\frac{.}{3}$ 37 C.F.R. §1.97 (b)(3) - (>3 mo. after filing direct or nat'l stage entry, but before 1^{st} O.A.)

This information disclosure statement is being submitted under 37 C.F.R. §1.97 (b)(3). Applicants have not received an Office Action on the merits in the present application. Therefore, no fee is believed to be due. However, in the event that this paper is crossing in the mail with a first Office Action on the merits, authorization is hereby given to charge the required fee pursuant to 37 C.F.R. §1.97(c) and 37 C.F.R. §1.17(p) to Deposit Account No. 16-2480 in the name of The Procter & Gamble Company. A duplicate of this letter is enclosed to facilitate charging of the fee, if necessary.

THE FOLLOWING IS ADDITIONAL INFORMATION PERTAINING TO (2) OR (3) MARKED WITH AN (X) ABOVE.

- (a) [] The Notification of Acceptance of this Application Under 35 U.S.C. §371 indicates that both a copy of the International Search Report and copies of the references cited therein are present in the national stage file. In accordance with MPEP §1893.03(g), it is respectfully requested that the Examiner note the consideration of these references in the first Office Action via the PTO-892 form.
- (b) [] The Notification of Acceptance of this Application Under 35 U.S.C. §371 indicates that a copy of the International Search Report is present in the national stage file. Copies of the references cited in that report are enclosed.
- (c) [] The Notification of Acceptance of this Application Under 35 U.S.C. §371 does <u>not</u> indicate that a copy of the International Search Report and copies of the references cited are present in the national stage file. Copies of the International Search Report and references are attached.
- 4. [] 37 C.F.R. §1.97 (b)(4) (before the mailing of a first Office Action after the filing of a request for continued examination under §1.114)

This information disclosure statement, submitted under 37 C.F.R. §1.97(b)(4), is being filed with the Request for Continued Examination (RCE) under 37 C.F.R. §1.114.

5. [] <u>Information to be Considered with CPA Filing</u>. This information disclosure statement is being filed with a Continued Prosecution Application (CPA) filed under 37 CFR 1.53(d).

6. [] 37 C.F.R. §1.97(c) with fee payment - (use after 1st Office Action & before Final Office Action or Notice of Allowance)

This information disclosure statement is being submitted under 37 C.F.R. §1.97(c). Applicant(s) have not received a final action under 37 C.F.R. §1.113, a notice of allowance under 37 C.F.R. §1.311, or an action that otherwise closes prosecution in the application (e.g., *Ex parte Quayle*) as of the date of this submission. Applicant(s) elect to pay the fee set forth in 37 C.F.R. §1.17(p). Please charge the fee set forth in 37 C.F.R. §1.17(p) to Deposit Account Number 16-2480 in the name of The Procter & Gamble Company. A duplicate copy of this letter is enclosed to facilitate the charging of the fee.

Company. A duplicate copy of this letter is enclosed to facilitate the charging of the fee.
ADDITIONAL ITEMS TO BE NOTED BY THE EXAMINER:
[] (1) Copies of the cited references were previously cited by or submitted to the USPTO in prior application Case No, U.S. Patent Application Serial No, filed Applicants claim priority to said application under 35 U.S.C. §120. Accordingly, copies of those documents are not provided with this
Statement, pursuant to 37 C.F.R. §1.98(d).
OR
[X] (2) Copies of the cited documents are enclosed.
OR
[] (3) Copies of all said documents, except document No.'s, were submitted and
considered in parent application U.S. Patent Application Serial No, filed
Applicant(s) claim priority to said application under 35 U.S.C. §120. Accordingly, copies of document
No.'s are not provided with this Statement, pursuant to 37 C.F.R. §1.98(d). Copies
of document No.'s are enclosed. It is respectfully requested that the cited documents be
carefully considered by the Examiner and made of record in this case.
[] (4) Pursuant to 37 C.F.R. §1.98(c), a concise explanation of the relevance of each cited reference that is not in the English language is provided.
[X] (5) Applicants also respectfully request the Examiner to consider and make of record the copending applications listed on the attached page.

Additional information is attached.

Respectfully submitted,

Ву

Larry L. Huston

Attorney

Registration No. 32,994 Customer Number: 27752

(513) 634-9358

February

,120

COPENDING APPLICATIONS

Atty. Docket No. Serial Number Inventor(s) Filing Date

8782 10/027,616 Shanov, et al. December 21, 2001

Approved for use through 10/31/2002 OMB 0651-0031

Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE Paperwork Reduction Act of 1995, no persons are required to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

SHEET 1 of 1

d to a confection of information unites	is it contains a valid ONB condor ituitibet
COMPI	LETE IF KNOWN
Application Number	10/027,646
Confirmation Number	入事
Filing Date	December 21, 2001
First Named Inventor	Saswati Datta et al.
Group Art Unit	O S
Examiner Name	0
Attorney Docket Number	8821L\$

U. S. PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No.1	DOCUMENT NUMBER Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
		US-5,236,512	08/17/1993	Rogers et al.	
		US-5,387,842	02/07/1995	Roth et al.	
		US-5,403,453	04/04/1995	Roth et al.	
		US-5,671,045	09/23/1997	Woskov et al.	
		US-5,961,772	10/05/1999	Selwyn	
		US-6,005,349	12/21/1999	Kunhardt et al.	
		US-6,081,329	06/27/2000	Cohn et al.	
		US-6,262,523 B1	07/17/2001	Selwyn et al.	

FOREIGN PATENT DOCUMENTS

		FOREIGN PATENT DOCUMENT					Pages, Columns, Lines Where Relevant Passages	
EXAMINER INITIALS*	Cite No.1	Country	y Code ³ Number ⁴	Kind Code⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	or Relevant Figures Appear	T ⁶
		wo	01/44790	A1	06/21/2001	Korfiatis et al.		
	l	DE	19605226	A1	08/14/1997	Gericke et al.		X
		JP	2001-159074		06/12/2001	Kataoka Seiichi		X

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

EXAMINER INITIALS*	Cite No.1	No. serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published				
TAKAKI, et al., "Multipoint Barrier Discharge Process for Removal of NOx from Diesel Engine Exhaust", IEEE TRANSACTIONS ON PLASMA SCIENCE, Vol 29, No. 3, June 2001. BAYER, et al., "Overall kinetics of SiO _x remote-PECVD using different organosilicon monomers", SURFACE AND COATINGS TECHNOLOG 116-119 (1999), pp. 874-878.						
						KARCHES et al., "A circulating fluidized bed for plasma-enhanced chemical vapor deposition on powders at low temperatures", SURFACE AND COATINGS TECHNOLOGY 116-119 (1999) pp. 879-885.
		ASTEX®, "Downstream Sources for Etch and Deposition," February 1, 1991, Applied Science Technology, Inc., Woburn, Mass.				
		ASTEX®, "Providing Innovation in Plasma, Power and Reactive Gases," JanFeb., 2001, Applied Science Technology, Inc., Woburn, Mass.				
		AX7200, Atmospheric Plasma Torch instructions, received May, 2001.				
EXAMINER DATE CONSIDERED						

EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, D.C. 20231.